Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
efinitidone hydrochloride
- Development stage
- Phase 1
- Lead developer
- Sunshine Lake Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Efinitidone hydrochloride is a small molecule anti-fibrotic agent developed by Sunshine Lake Pharma (a subsidiary of HEC Pharm) for the treatment of idiopathic pulmonary fibrosis (IPF). It is a derivative of pirfenidone, designed to inhibit the synthesis of pro-fibrotic cytokines, particularly transforming growth factor-beta (TGF-beta) and tumor necrosis factor-alpha (TNF-alpha). By modulating these pathways, efinitidone aims to reduce fibroblast proliferation and collagen deposition in the lungs, thereby slowing the progression of fibrosis. The drug was developed to offer improved pharmacokinetic properties and a better safety profile compared to the parent compound. It has advanced into Phase 2 clinical trials in China to evaluate its efficacy and safety in patients with IPF.
- Other names
- 依非尼酮盐酸依非尼酮efinitidone
02
Targets
TGFB (GARP–latent transforming growth factor beta 1 complex)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on efinitidone hydrochloride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on efinitidone hydrochloride.